Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 43 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 53%, bearish.
Out of all of the special options we uncovered, 23 are puts, for a total amount of $843,905, and 20 are calls, for a total amount of $1,932,867.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $560.0 to $1400.0 for Eli Lilly over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $560.0 to $1400.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | CALL | SWEEP | NEUTRAL | 09/20/24 | $138.15 | $132.45 | $135.86 | $820.00 | $678.0K | 315 | 0 |
LLY | CALL | TRADE | BEARISH | 01/17/25 | $191.75 | $188.0 | $188.98 | $790.00 | $188.9K | 486 | 10 |
LLY | CALL | TRADE | NEUTRAL | 12/19/25 | $146.0 | $139.05 | $142.55 | $1000.00 | $142.5K | 77 | 10 |
LLY | CALL | TRADE | BEARISH | 01/17/25 | $411.8 | $406.6 | $407.65 | $560.00 | $122.2K | 306 | 3 |
LLY | CALL | TRADE | NEUTRAL | 10/18/24 | $39.3 | $38.05 | $38.57 | $950.00 | $115.7K | 165 | 16 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $998.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
Posted In: LLY